Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4224 Target Snapshot

Dual specificity protein kinase CLK1 · SINGLE PROTEIN · Homo sapiens

2,079Compounds
515Assays
22Approved Drugs
1,666.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P49759. Use UniProt P49759 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P49759 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dual specificity protein kinase CLK1 as ChEMBL target CHEMBL4224, mapped to UniProt P49759. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dual specificity protein kinase CLK1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4224
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P49759
Dual specificity protein kinase CLK1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Dual specificity protein kinase CLK1 is the right protein anchor across sources, using UniProt P49759 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDual specificity protein kinase CLK1
UniProt AccessionP49759
Component TypeProtein
Sequence Length484 aa

Dual specificity protein kinase CLK1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Dual specificity protein kinase CLK1, mapped to UniProt P49759. Sequence length is 484 aa.

Mapped IDP49759
Review nameDual specificity protein kinase CLK1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

22
Approved
14
Phase III
21
Phase II
19
Phase I
Assay Mix

Activity Type Distribution

IC501,182.0
KI8.0
EC5045.0
KD431.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4784318 10.74 Kd 0.018 Preclinical
CHEMBL393525 10.25 Kd 0.056 Preclinical
CHEMBL5653589 9.65 Kd 0.224 Preclinical
CHEMBL4441878 9.64 Kd 0.228 Preclinical
CHEMBL4647659 9.6 Kd 0.254 Preclinical
CHEMBL5070553 9.49 Kd 0.326 Preclinical
CHEMBL5426285 9.41 Kd 0.388 Preclinical
CHEMBL5081787 9.4 Kd 0.395 Preclinical
CHEMBL1230165 9.27 Kd 0.54 Clinical
CHEMBL5279705 9.24 Kd 0.58 Preclinical
Distribution

pChEMBL Value Distribution

60
5.0
107
5.5
143
6.0
142
6.5
220
7.0
238
7.5
95
8.0
19
8.5
14
9.0
3
9.5
pChEMBL
Approved Drugs

Approved Drugs

TOVORAFENIB
CHEMBL3348923
Approved 2024
CAPIVASERTIB
CHEMBL2325741
Approved 2023
MOMELOTINIB
CHEMBL1078178
Approved 2023
PACRITINIB
CHEMBL2035187
Approved 2022
ABEMACICLIB
CHEMBL3301610
Approved 2017
BRIGATINIB
CHEMBL3545311
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
BARICITINIB
CHEMBL2105759
Approved 2017
PALBOCICLIB
CHEMBL189963
Approved 2015
NINTEDANIB
CHEMBL502835
Approved 2014
BOSUTINIB
CHEMBL288441
Approved 2012
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

515
Total Assays
948
Tested Compounds
3
Assay Types
Binding — 509 assays, 948 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 367 456 7.0
assay format 81 136 6.5
cell-based format 59 320 7.1
biochemical format 1 0
subcellular format 1 36 6.5
Functional — 4 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 3 1 5.9
assay format 1 0
ADME — 2 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 1 6.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine